XML 43 R31.htm IDEA: XBRL DOCUMENT v3.19.2
Intangible Assets - Additional Information (Detail) - USD ($)
3 Months Ended 9 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Finite Lived Intangible Assets [Line Items]        
Amortization expense $ 425,107 $ 425,107 $ 1,275,322 $ 1,275,322
Amortization of license agreements remainder of fiscal year 2019 425,107   425,107  
Amortization of license agreements in 2020 1,700,429   1,700,429  
Amortization of license agreements in 2021 1,700,429   1,700,429  
Amortization of license agreements in 2022 1,700,429   1,700,429  
Amortization of license agreements in 2023 1,700,429   1,700,429  
Amortization of license agreements, thereafter 10,261,865   $ 10,261,865  
Novartis | Licensing Agreement        
Finite Lived Intangible Assets [Line Items]        
Amortization period of intangible assets     21 years  
Finite-lived intangible assets, accumulated amortization 643,090   $ 643,090  
Novartis | Patents        
Finite Lived Intangible Assets [Line Items]        
Amortization period of intangible assets     14 years  
Finite-lived intangible assets, accumulated amortization $ 6,725,437   $ 6,725,437